Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change Price Change
B 169.68 0.65% 1.09
ABBV closed up 0.65 percent on Monday, June 17, 2024, on 80 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
19 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Stochastic Reached Overbought Strength 0.00%
Multiple of Ten Bearish Other 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
NR7 Range Contraction 1.87%
Overbought Stochastic Strength 1.87%
Overbought Stochastic Strength 2.16%
Stochastic Sell Signal Bearish 1.18%
Slingshot Bullish Bullish Swing Setup 1.18%
Multiple of Ten Bearish Other 1.18%

   Recent Intraday Alerts

Alert Time
Up 1% about 10 hours ago
Rose Above Previous Day's High about 10 hours ago
10 DMA Support about 10 hours ago
Up 1% 3 days ago
60 Minute Opening Range Breakout 3 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

AbbVie Inc. Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh├žet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Pharmaceutical Plastic Autoimmune Disease Infection Psoriasis Ulcerative Colitis Regenerative Medicine Anemia Depressive Disorder Hepatitis C Atopic Dermatitis Crohn's Disease Hematological Malignancies Hepatitis C Virus Constipation Irritable Bowel Syndrome Blood Cancers Immunosuppressants Migraine Skincare Products Psoriatic Arthritis Adalimumab Endometriosis Ocular Hypertension Treatment Of Migraine Uterine Fibroid Advanced Prostate Cancer Chronic Idiopathic Constipation Combination Drugs Eye Care Products Genotype Hypothyroidism Severe Plaque Psoriasis Spondylitis

Is ABBV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 181.1978
52 Week Low 125.8516
Average Volume 5,101,150
200-Day Moving Average 157.69
50-Day Moving Average 163.68
20-Day Moving Average 163.25
10-Day Moving Average 167.47
Average True Range 3.14
RSI (14) 61.09
ADX 22.96
+DI 29.96
-DI 17.52
Chandelier Exit (Long, 3 ATRs) 161.34
Chandelier Exit (Short, 3 ATRs) 162.99
Upper Bollinger Bands 173.32
Lower Bollinger Band 153.18
Percent B (%b) 0.82
BandWidth 12.34
MACD Line 1.55
MACD Signal Line 0.64
MACD Histogram 0.9072
Fundamentals Value
Market Cap 299.58 Billion
Num Shares 1.77 Billion
EPS 2.72
Price-to-Earnings (P/E) Ratio 62.38
Price-to-Sales 5.68
Price-to-Book 25.41
PEG Ratio 1.62
Dividend 5.99
Dividend Yield 3.53%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 174.24
Resistance 3 (R3) 173.97 172.19 173.48
Resistance 2 (R2) 172.19 171.03 172.32 173.23
Resistance 1 (R1) 170.93 170.31 171.56 171.20 172.97
Pivot Point 169.15 169.15 169.46 169.28 169.15
Support 1 (S1) 167.89 167.99 168.52 168.16 166.39
Support 2 (S2) 166.11 167.27 166.24 166.13
Support 3 (S3) 164.85 166.11 165.88
Support 4 (S4) 165.12